Form of Incentive Stock Option Agreement under 2022 Equity Incentive Plan
Exhibit 10.2
KARYOPHARM THERAPEUTICS INC.
STOCK OPTION AGREEMENT
Karyopharm Therapeutics Inc. (the “Company”) hereby grants the following stock option pursuant to its 2022 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof.
Notice of Grant
Name of optionee (the “Participant”): |
|
Grant Date: |
|
Incentive Stock Option or Nonstatutory Stock Option: |
|
Number of shares of the Company’s Common Stock subject to this option (“Shares”): |
|
Option exercise price per Share: |
|
Number, if any, of Shares that vest immediately on the grant date: |
|
Shares that are subject to vesting schedule: |
|
Vesting Start Date: |
|
Final Exercise Date: |
|
Vesting Schedule:
Vesting Date | Number of Shares That Vest |
One Year from Vesting Start Date: |
|
Each Successive Month Thereafter: |
|
Four Years from Vesting Start Date: |
|
All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein. |
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
| Karyopharm Therapeutics Inc. |
___________________ |
|
___________________ | By:_________________________________ Name of Officer: Michael Mason Title: Chief Financial Officer |
___________________ |
- 1 -
KARYOPHARM THERAPEUTICS INC.
Stock Option Agreement
Incorporated Terms and Conditions
This agreement evidences the grant by the Company, on the grant date (the “Grant Date”) set forth in the Notice of Grant that forms part of this agreement (the “Notice of Grant”), to the Participant of an option to purchase, in whole or in part, on the terms provided herein and in the Company’s 2022 Equity Incentive Plan (the “Plan”), the number of Shares set forth in the Notice of Grant of common stock, $0.0001 par value per share, of the Company (“Common Stock”), at the exercise price per Share set forth in the Notice of Grant. Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant (the “Final Exercise Date”).
It is intended that the option evidenced by this agreement shall be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”) to the maximum extent permitted by law, solely to the extent designated as an incentive stock option in the Notice of Grant. Except as otherwise indicated by the context, the term “Participant”, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms.
This option will become exercisable (“vest”) in accordance with the vesting schedule set forth on the cover page of this agreement (the “Vesting Schedule”). Any fractional shares resulting from the application of any percentages used in the Vesting Table shall be rounded down to the nearest whole number of shares of Common Stock (except for the last vesting tranche).
Notwithstanding the foregoing, to the extent that the Participant is a party to an employment agreement or other agreement with the Company that provides vesting terms that differ from the Vesting Schedule, the terms set forth in such employment agreement or other agreement shall prevail.
The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section 3 hereof or the Plan.
- 2 -
- 3 -
This option may not be sold, assigned, transferred, pledged, or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant.
The Participant acknowledges that in accepting this award, the Participant will be bound by any clawback policy that the Company has in place or may adopt in the future.
This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.
- 4 -
ANNEX A
KARYOPHARM THERAPEUTICS INC.
Stock Option Exercise Notice
Karyopharm Therapeutics Inc.
85 Wells Ave
Newton, MA 02459
Dear Sir or Madam:
I, _____________________ (the “Participant”), hereby irrevocably exercise the right to purchase __________shares of the Common Stock, $0.0001 par value per share (the “Shares”), of Karyopharm Therapeutics Inc. (the “Company”) at $___________ per share pursuant to the Company’s 2022 Equity Incentive Plan and a stock option agreement with the Company dated _____(the “Option Agreement”). Enclosed herewith is a payment of $_________, the aggregate purchase price for the Shares. The certificate for the Shares should be registered in my name as it appears below or, if so indicated below, jointly in my name and the name of the person designated below, with right of survivorship.
Dated: _______________________________
_____________________________________
Signature
Print Name:
Address:
_____________________________________
_____________________________________
Name and address of persons in whose name the Shares are to be jointly registered (if applicable):
_____________________________________
- 5 -